Pliant Therapeutics News

MASI, PLRX and CGC Are Among After Hour Movers

Seeking AlphaMar 22 16:59 ET

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)

TipRanksMar 13 07:11 ET

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)

TipRanksMar 12 12:50 ET

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m

Simply Wall StMar 6 05:10 ET

Pliant Therapeutics Price Target Raised to $54.00/Share From $50.00 by RBC Capital

Pliant Therapeutics Price Target Raised to $54.00/Share From $50.00 by RBC Capital

Dow JonesMar 5 10:37 ET

RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept

Pliant Therapeutics (PLRX) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $33 to $54. Price: 16.6, Change: +0.21, Percent Change: +1.28

MT NewswiresMar 5 07:57 ET

Express News | HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $48 Price Target

Moomoo 24/7Feb 28 12:52 ET

RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk

RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk.

MT NewswiresFeb 28 08:04 ET

Piper Sandler Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)

TipRanksFeb 28 07:31 ET

Pliant Therapeutics (PLRX) Gets a Buy From RBC Capital

TipRanksFeb 28 07:16 ET

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX) and Viridian Therapeutics (VRDN)

TipRanksFeb 28 06:50 ET

Express News | Needham Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target

Moomoo 24/7Feb 28 05:28 ET

Analysts' Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX)

TipRanksFeb 27 22:20 ET

Pliant Therapeutics (PLRX) Receives a Buy From TD Cowen

TipRanksFeb 27 21:27 ET

Express News | Pliant Therapeutics Q4 2023 GAAP EPS $(0.69) Beats $(0.82) Estimate

Moomoo 24/7Feb 27 17:18 ET

Pliant Therapeutics 4Q Loss $41.1M >PLRX

Pliant Therapeutics 4Q Loss $41.1M >PLRX

Dow JonesFeb 27 16:03 ET

Buy Rating on Pliant Therapeutics: Positive Outlook on Bexotegrast Despite Investor Concerns

TipRanksFeb 7 08:31 ET

Oppenheimer Adjusts Pliant Therapeutics Price Target to $47 From $49, Maintains Outperform Rating

Pliant Therapeutics (PLRX) has an average rating of buy and price targets ranging from $33 to $53, according to analysts polled by Capital IQ. Price: 15.31, Change: -0.49, Percent Change: -3.1

MT NewswiresFeb 6 09:14 ET

Pliant Therapeutics Achieves Success in Liver Disease Trial

TipRanksFeb 6 04:16 ET

Pliant Therapeutics Is Maintained at Buy by Needham

Pliant Therapeutics Is Maintained at Buy by Needham

Dow JonesFeb 5 14:04 ET